** Shares of Israel-based medical device maker IceCure Medical ICCM.O fall 17% to $1.22 in afternoon trading, their biggest one-day percentage fall in more than a year
** ICCM says it expects the FDA to make a decision on its ProSense system, used for the treatment of a type of breast cancer, after Q1 2025
** Co previously expected FDA's decision by Q1 2025
** Co's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them
** ICCM has risen 19.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。